HDACs and HDAC Inhibitors in Cancer Development and Therapy.
about
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.Targeting the epigenome in malignant pleural mesotheliomaEnhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53.The nature of the GRE influences the screening for GR-activity enhancing modulators.Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to TherapyConcomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.LncRNA-uc002mbe.2 Interacting with hnRNPA2B1 Mediates AKT Deactivation and p21 Up-Regulation Induced by Trichostatin in Liver Cancer Cells.Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.Acetylation and deacetylation in cancer stem-like cells.Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.Natural Agents-Mediated Targeting of Histone Deacetylases.Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases.The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.Nuclear Lipid Mediators: Role of Nuclear Sphingolipids and Sphinosine-1-Phosphate Signaling in Epigenetic Regulation of Inflammation and Gene Expression.Combination Therapies Targeting HDAC and IKK in Solid Tumors.Roles of HDACs in the Responses of Innate Immune Cells and as Targets in Inflammatory Diseases.Emerging Roles for Epigenetic Programming in the Control of Inflammatory Signaling Integration in Heath and Disease.A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration.Epigenetic Modifications: Insight into Oligodendrocyte Lineage Progression, Regeneration and Disease.Epigenetic Treatment Options in Urothelial Carcinoma.Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.GDF11/BMP11 as a novel tumor marker for liver cancer.Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells.Computer-Aided Drug Design in Epigenetics.Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Prognostic Value of Nicotinamide N-Methyltransferase Expression in Patients With Solid Tumors: A Systematic Review and Meta-AnalysisAberrant O-glycosylation modulates aggressiveness in neuroblastomaDifferential HDAC1/2 network analysis reveals a role for prefoldin/CCT in HDAC1/2 complex assemblyFood Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart FailureNext-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation
P2860
Q33733042-16CCCFED-7B0E-4D9F-91B7-3A66C4FFE027Q33890546-C1FA1C14-D66A-4F4D-99AD-D0198CDD3BA3Q36298507-64018476-22FC-42B7-9A90-881624EF6030Q36390683-C1A5A62F-ED2F-4A39-8012-F8D54C5D88F8Q38697860-22628454-0050-4CC1-8AF4-C05773FD10B5Q38733838-09D43825-EB70-433A-B32F-738353F04488Q39433158-9B6C9764-9D27-4A3B-A440-EB82B2298E73Q41084074-E8E4DFBB-2765-4C49-B058-17ADD729896FQ42367872-B9522A2F-5765-4868-B57B-58B443C599A8Q46477219-56D70B6B-EEBF-416D-9B51-CF0C5A78B59FQ47106297-32B4A003-B4ED-4483-AB72-4F6EF1DD3B64Q47445768-0E5B87D4-04B2-4C31-8A77-F75869C5919EQ47631371-EDAA8C45-B164-4FCA-A081-B0E1AEEAFA0FQ47740361-1BFB8F32-DB5D-4B08-8DB1-9BC4B2EB82C7Q48276563-4E9C1020-5AF7-4605-9F61-96116E7D764AQ49375826-12D78BDD-1E76-47F7-AE2E-BEF9C232747BQ49610036-BE92727C-8866-4388-8244-A0651E489C74Q49887757-93FEA5C4-5D47-47DB-9DB9-59CC9D0631C3Q50045985-36C9D517-1A1A-41F1-8EB4-56AFE9ED4EE3Q50045989-778C2A0A-8927-4B8A-B631-1AD42ACC05DFQ50065994-668FC973-824A-4638-8F8F-56AEC154D15FQ50087630-2620720E-2EC5-4F12-B584-BB8F6C7340F9Q50182584-F71AE61D-EAF8-40D5-BDE7-7ED0F5BCCE7DQ50326769-E7543BEB-7461-4F2E-8F43-B79BC77C5D7AQ52590685-1D106105-C20F-4B68-8AAD-F0D3C73D86DBQ52653059-B0EC2AA1-C633-4F92-9FD4-634F3BBF63E7Q54988474-A307B843-3D38-46CD-8A32-D4FC16FF645BQ55120002-2954E553-EA58-4D2F-B8B9-02D57DB8ECD3Q55485574-C27BFCF6-9429-42DF-B443-78DCAD94C067Q57817606-83F6FC3B-B57B-4EE0-985E-11232F3594E8Q57821545-E8FF1073-704E-4AF3-BFDD-136943A0D4A2Q58747393-76894749-388F-4B9F-9EAF-320934E6F1BFQ58766782-06C0796F-5B35-4A01-9BF2-C574CAF85BB9Q58798742-0B41B657-222A-4EB0-BF59-762FC01CA8A2
P2860
HDACs and HDAC Inhibitors in Cancer Development and Therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
HDACs and HDAC Inhibitors in Cancer Development and Therapy.
@en
type
label
HDACs and HDAC Inhibitors in Cancer Development and Therapy.
@en
prefLabel
HDACs and HDAC Inhibitors in Cancer Development and Therapy.
@en
P2860
P1476
HDACs and HDAC Inhibitors in Cancer Development and Therapy.
@en
P2093
Edward Seto
P2860
P356
10.1101/CSHPERSPECT.A026831
P577
2016-09-06T00:00:00Z